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Intralesional triamcinolone acetonide injection in hypertrophic
skin surrounding the percutaneous titanium implant of a
bone-anchored hearing aid
Abstract
Objective:We present a patient with persistent hypertrophic skin surrounding the percutaneous implant
of a bone-anchored hearing aid system, successfully treated with intralesional applied
corticosteroids.Method:Case report and review of the world literature concerning bone-anchored hearing
aid implantation and intralesional applied corticosteroids for the treatment of hypertrophic scars and
keloids.Results:Eight weeks after revision surgery to reduce surplus skin and subcutaneous scar tissue
overgrowing the abutment, skin and subcutaneous scar tissue overgrowth reoccurred. As an alternative
to yet another surgical procedure, the hypertrophic skin was treated with intralesional injections of
triamcinolone acetonide. Three weeks after the treatment, a satisfying result was seen, and no
subsequent relapse was observed.Conclusion:To our knowledge, this is the first, photographically well
documented case report of a patient with persistent hypertrophic skin surrounding a percutaneous
bone-anchored hearing aid implant, successfully treated with intralesional applied corticosteroids.
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Abstract
Objective: We present a patient with persistent hypertrophic skin surrounding the percutaneous implant of a
bone-anchored hearing aid system, successfully treated with intralesional applied corticosteroids.
Method: Case report and review of the world literature concerning bone-anchored hearing aid implantation
and intralesional applied corticosteroids for the treatment of hypertrophic scars and keloids.
Results: Eight weeks after revision surgery to reduce surplus skin and subcutaneous scar tissue overgrowing
the abutment, skin and subcutaneous scar tissue overgrowth reoccurred. As an alternative to yet another surgical
procedure, the hypertrophic skin was treated with intralesional injections of triamcinolone acetonide. Three
weeks after the treatment, a satisfying result was seen, and no subsequent relapse was observed.
Conclusion: To our knowledge, this is the first, photographically well documented case report of a patient with
persistent hypertrophic skin surrounding a percutaneous bone-anchored hearing aid implant, successfully
treated with intralesional applied corticosteroids.
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Introduction
The bone-anchored hearing aid (BAHA) represents an
alternative to the conventional bone-conduction hearing
aid (fitted to a headband or onto a specially strengthened
spectacle). The BAHA system, in which the transducer is
fitted onto a percutaneous coupling device attached to a tita-
nium fixture placed in the temporal bone, has both cosmetic
and acoustic advantages over the conventional bone con-
duction hearing aid, and has known quality of life benefits.1
In the early 1980s, Tjellstro¨m and Ha˚kansson published
the first clinical BAHA studies.2 Over time, the implan-
tation procedure has been simplified. For adults, the stan-
dard two-stage surgical procedure for inserting the
percutaneous implant into the temporal bone has been
converted to a single-stage procedure in which the percuta-
neous coupling device (abutment) is premounted onto a
self-tapping screw fixture. As a result of positive experience
with the BAHA for conventional indications, and the low
rate of predominantly minor complications,3–5 the indi-
cations for BAHA continue to grow, extending to severe
unilateral hearing loss and to cases of unilateral conductive
or mixed hearing loss which traditionally have been left
unaided.6,7
Insertion of the percutaneous implant may sometimes
give rise to adverse skin reactions. Several large studies
reported an average occurrence of adverse skin reactions
in adults of 15 per cent (10–20 per cent), most of which
can be successfully treated in an office setting. Implant
extrusion is the most severe complication, although rare
(average occurrence 5 per cent (2.5–10 per cent)), and
may be the result of trauma, inadequate osseo-integration
or inflammatory processes.3–5 An important predisposing
factor for adverse skin reactions is the mobility of the skin
surrounding the abutment. Therefore, a vital part of the sur-
gical procedure is the reduction of subcutaneous tissue so
that the skin is sufficiently thin, firmly attached to the under-
lying periosteum and without hair follicles.8 In some
patients, however, independent of the technique used to
reduce subcutaneous tissue,9–11 the skin hypertrophies and
pushes up against the implant abutment, in some cases
even growing over it, jeopardising the accessibility of the
abutment for the transducer coupling. If hypertrophic skin
persists and does not respond to conservative treatment
(e.g. application of antibiotic and corticosteroid ointment),
revision surgery is needed. At the department of otorhino-
laryngology of the Radboud University Medical Center,
approximately 6 per cent of the patients have required revi-
sion surgery of the surrounding skin for this indication.
Revision surgery may not be applicable or desirable in
some patients, and alternative methods of treatment are
required. We present a patient with persistent hypertrophic
skin surrounding the percutaneous implant, successfully
treated with intralesional applied corticosteroids.
Case report
Eight months after his initial BAHA implant, a 62-year-
old man underwent revision surgery to reduce and thin
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the surplus of skin and subcutaneous scar tissue overgrow-
ing the abutment. The pre-operative condition is shown in
Figure 1.
After local anaesthesia, a straight incision of approxi-
mately 3 cm was made, with the percutaneous abutment
at the centre of the incision. Both sides of the incision
were thinned out, removing all subcutaneous tissue but
leaving the periosteum.
Post-operative care consisted of a bolster dressing under
a healing cap for one week. Figure 2 shows the post-
operative condition directly after removal of the healing
cap and bolster dressing.
Despite a good initial result, with the patient being able to
wear his BAHA without any problems or complaints, after
six to eight weeks the skin and subcutaneous scar tissue
overgrowth reoccurred (Figure 3). As an alternative to yet
another surgical procedure, the hypertrophic skin was
treatedwith intralesional injections of a total of 1 mlof triam-
cinolone acetonide 40 mg/ml, using a 30-gauge needle on a
Luer-lock syringe, without any preceding local anaesthesia.
The injection was well tolerated by the patient. After just a
few days, he noticed that coupling the BAHA transducer
on the abutment became easier.
Three weeks after the triamcinolone treatment, a satisfy-
ing result was seen (Figure 4). No relapse was seen over the
subsequent six months.
Discussion
The use of triamcinolone acetonide injections for the treat-
ment of hypertrophic scars and keloids has been shown to be
FIG. 1
Pre-operative condition. The skin surrounding the abutment is
hypertrophic and has partly covered the percutaneous implant.
FIG. 2
Oneweekpost-operativeappearance, immediatelyafter removing
the healing cap and bolster dressing.
FIG. 3
Eight week post-operative appearance. The hypertrophic scar
tissue has recurred.
FIG. 4
Appearance three weeks after intralesional treatment with
1 ml triamcinolone acetonide 40 mg/ml (three weeks after
Figure 3).
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effective in some patients, and has been in use for several
decades.12,13 In the majority of patients, multiple intrale-
sional injections are needed to obtain the desired clinical
effect, i.e. flattening of the lesion and cessation of itching.
In the long term, the recurrence rate may rise to 50 per
cent.12 The main effect of intralesional steroids on the con-
nective tissue of keloids is a decrease in viscosity due to a
loss of ground substance.14 Few complications have been
documented, and are limited to local skin changes or pain
as a result of the injection. Rarely, Cushing’s syndrome
has been described, usually self-limiting. However, in chil-
dren, features of Cushing’s syndrome may be protracted.
Therefore, the dosages of intralesional steroids normally
recommended for adults are inappropriate for children.15
. Siting of a percutaneous bone-anchored hearing aid
(BAHA) implant may give rise to adverse skin
reactions
. This paper describes a patient with persistent
hypertrophic skin surrounding the percutaneous
implant of his BAHA system, which was
successfully treated with intralesional applied
corticosteroids
. In order to confirm the effectiveness of this
treatment mode, long term results need to be
documented in a considerable number of patients
Skin and subcutaneous scar tissue overgrowing the
BAHA abutment is a troublesome condition, often
causing the patient discomfort and pain, and difficulty in
coupling the transducer. Although in some cases conserva-
tive treatment may be successful, revision surgery will be
required in most patients. The intralesional application of
triamcinolone acetonide may prove to be a worthwhile
alternative. In our current patient, at the time of writing,
no side effects of the treatment have been observed, and
the result is satisfactory and sustained. In order to
confirm the effectiveness of this treatment mode, long
term results will need to be documented in a considerable
number of patients.
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